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Abstract: The Cdc2-like kinases (CLKs) regulate RNA splicing and have been shown to suppress cell growth. 
Knockdown of CLK2 was found to block glioma stem-like cell (GSC) growth in vivo through the AKT/FOXO3a/p27 
pathway without activating mTOR and MAPK signaling, suggesting that these pathways mediate resistance to CLK2 
inhibition. We identified CLK2 binding partners using immunoprecipitation assays and confirmed their interactions 
in vitro in GSCs. We then tested the cellular viability of several signaling inhibitors in parental and CLK2 knockdown 
GSCs. Our results demonstrate that CLK2 binds to 14-3-3τ isoform and prevents its ubiquitination in GSCs. Stable 
CLK2 knockdown increased PP2A activity and activated PI3K signaling. Treatment with a PI3K/mTOR inhibitor in 
CLK2 knockdown cells led to a modest reduction in cell viability compared to drug treatment alone at a lower 
dose. However, FGFR inhibitor in CLK2 knockdown cells led to a decrease in cell viability and increased apoptosis. 
Reduced expression of CLK2 in glioblastoma, in combination with FGFR inhibitors, led to synergistic apoptosis in-
duction and cell cycle arrest compared to blockade or either kinase alone.
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Introduction
Receptor tyrosine kinases are cell surface re- 
ceptors that orchestrate major signaling path-
ways such as Ras/MAPK/ERK and Ras/PI3K/
AKT [1]. The receptor tyrosine kinase family 
includes six tyrosine kinase receptors; of these, 
epidermal growth factor (EGFR) and the struc-
turally related ErbB2/HER2 are amplified and 
mutated in 45%-57% and 8%-41% of glioblas-
toma patients, respectively [2, 3]. Another re- 
ceptor of the tyrosine kinase family, fibroblast 
growth factor receptor (FGFR), is amplified in a 
subset of 3.2% of glioblastoma cases, as 
reported by The Cancer Genome Atlas studies 
[3]. These receptor tyrosine kinases down-
stream signaling pathways are involved in the 
regulation of various cellular processes, includ-
ing cell proliferation, survival, and differen- 
tiation. 
Upon the activation of EGFR and FGFR, activat-
ed AKT phosphorylates, both the FOXO family, 
which inhibits pro-apoptotic signaling, and the 
mammalian target of rapamycin (mTOR)/S6- 
kinase pathways; this results in increased cell 
proliferation and tumor growth. Cancer cells 
maintain mTOR activation despite suppressed 
PI3K/AKT signaling [4]. Therefore, dual PI3K/
mTOR inhibitors have improved therapeutic 
effects on tumor cells compared with either 
inhibitor alone and are currently being tested in 
clinical trials. GSK2126458 is a dual PI3K/
mTOR inhibitor that was evaluated in a phase 1 
clinical trial in solid tumors and lymphoma in 
2017 [5]. Activation of Ras changes GDP to GTP 
and regulates MAP kinase and ERK phosphory-
lation. Inhibitors and antibodies targeting these 
pathways have had varied success in the treat-
ment of glioblastoma [6]. Despite preclinical 
and early-phase clinical testing of various spe-
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cific tyrosine kinase pathway inhibitors, target-
ing these pathways in glioblastoma had limited 
success in the clinic. More effective therapies 
targeting critical signaling elements in glioblas-
toma are needed to prolong the survival of 
patients with this deadly disease. 
In our previous study, we found that CLK2 was 
expressed at high levels in glioblastoma, where 
it regulates the AKT/FOXO3a/p27 pathway [7]. 
High expression of CLK2 in glioblastoma tissue 
is correlated with poor outcome. Although 
CLK2 depletion was found to be beneficial for 
survival in preclinical glioblastoma models, sev-
eral other signaling cascades remain activated. 
In cases of insulin-induced AKT activation, 
CLK2 phosphorylates the phosphatase 2A 
(PP2A) regulatory subunit B56β, which dephos-
phorylates the phosphor AKT site (S473 and 
T308) [8]. Heterodimeric PP2A is formed from 
the combination of three subunits: a catalytic 
subunit (C), a regulatory subunit (B), and scaf-
folding (A) [9]. Among the B subunits, B55 is 
important in PP2A’s specificity for AKT [10]. 
Proteasome inhibition results in an accumula-
tion of CLK2 in neurons, but not in Shank3-
deficient neurons [11, 12]. In addition, CLK2 
inhibition has been shown to result in reduced 
tumor growth and proliferation in MYC-amplified 
breast cancer [13]. Given the central role of 
CLKs in the phosphorylation of serine/arginine-
rich proteins, which control a wide variety of 
cellular functions such as splicing and protein 
stabilization, it is vital to study specific CLK 
functions in cancer cells.
14-3-3 protein has known modulatory func-
tions that regulate multiple signaling pathways 
through binding with Ser/Thr-phosphorylated 
motifs on the target protein [14]. The protein 
has several isoforms, with at least seven (β, γ, 
ε, σ, ζ, τ, and η) in mammals [15]. Depending on 
the binding target protein, 14-3-3 protein 
affects the stability, localization, or association 
of target proteins [16]. The recognition motif 
between AKT and 14-3-3 overlap [17]. Several 
AKT target proteins are regulated by 14-3-3 
protein, including FOXO protein, BAD p27Kip1, 
and YAP. Binding of 14-3-3 protein with FOXO 
is regulated via FOXO phosphorylation by AKT 
[18].
Given the various biological functions of CLK2 
and its high expression level in solid tumors, 
including glioblastoma, a better mechanistic 
understanding of its regulation in cancer is vital 
for the development of CLK2-based targeted 
therapy. We hypothesized that CLK2 combina-
tion therapy with multiple molecularly targeted 
agents would be a promising approach to over-
coming therapy resistance. 
Materials and methods
Cell lines and reagents
We isolated glioma stem-like cells (GSCs) from 
brain tumor specimens and cultured them at 
The University of Texas MD Anderson Cancer 
Center (Houston, TX). Acquisition of these cells 
was approved by the Institutional Review Board 
of MD Anderson. Glioma stem cell develop- 
ment is funded by the MD Anderson Brain 
Cancer SPORE supported by P50CA127001. 
The GSCs were cultured in Dulbecco’s modifi- 
ed Eagle’s medium-F12 medium (1:1) with B27 
(Invitrogen), basic fibroblast growth factor 
(bFGF; Sigma), and epidermal growth factor 
(EGF; Sigma) at 37°C in a humidified atmo-
sphere of 5% CO2 and 95% air. They were then 
tested and authenticated by DNA fingerprinting 
in the MD Anderson Cancer Center Cell Line 
Characterization Core. 293T embryonic kidney 
cells were obtained from the American Type 
Culture Collection (ATCC) and maintained in 
Dulbecco’s modified Eagle medium (Sigma), 
supplemented with 10% fetal bovine serum. All 
cell lines were free of mycoplasma contamina-
tion. Inhibitors of PI3K/mTOR1/2 (omipalisib 
[GSK2126458]; cat. #S2658), PI3K (BKM120; 
cat. #S2247), FGFR (LY2874455; cat. #S7057), 
and MEK (PD98059; cat. #S1177) were pur-
chased from Selleckchem. Okadaic acid (cat. 
#495604) was purchased from Calbiochem. 
Stable knockdown and overexpression of CLK2 
or knockdown of 14-3-3τ in GSCs
CLK2 inhibition in GSCs by shRNA mediated 
approaches have been described previously 
[7]. CLK2 lentiviral activation particles were 
purchased from Santa Cruz (sc-403326-LAC). 
14-3-3τ was purchased from Sigma (TRCN- 
0000078172).
Cell viability 
For the cell viability assay, 5 × 103 GSCs per 
well were cultured with specific inhibitors for 5 
days in a 96-well plate. A cell viability analysis 
was performed using a CellTiter-Glo lumines-
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cent cell viability assay (Promega), according to 
the manufacturer’s protocol. 
Cell cycle analysis and apoptosis assay
Vector-infected and CLK2 knockdown GSCs 
with specific inhibitors were incubated for 1 day 
(cell cycle) or 3 days (apoptosis). For the cell 
cycle analysis, cells were treated with a natural 
enzyme mixture (Accutase; Sigma), washed 
with 1 × phosphate-buffered saline (PBS), fixed, 
and permeabilized with cold 70% EtOH for 24 
hours at -20°C. After incubation, cells were 
washed three times with 1 × PBS and incubat-
ed with 500 μl of propidium iodide (BD Bio- 
sciences) for 30 minutes at 37°C. A flow cyto-
metric analysis was performed using at least 
10,000 cells, and the cell cycle phases were 
analyzed using a FACSCalibur flow cytometer 
(BD Biosciences). For the apoptosis assay, we 
used 5*105/100 μl of resuspended cells in 
Annexin V binding buffer, stained with 2 μl of 
Annexin V-APC (Biolegend) and 1 μg/ml of DAPI 
for 15 minutes at ambient temperature. 
Apoptosis was analyzed at the MD Anderson 
Flow Cytometry and Cellular Imaging Facility.
PP2A immunoprecipitation phosphatase assay
PP2A activity (cat. #17-313) was determined 
using the PP2A immunoprecipitation phospha-
tase assay kit from Millipore. The lysed cells 
were rotated for 2 h at 4°C with 4 μg of anti-
PP2A and protein agarose. After being washed 
three times, the cells were incubated for 10 
min in a 30°C shaking incubator with 60 μl of 
phosphopeptide and 20 μl of Ser/Thr assay 
buffer. The supernatant of the reaction (25 μl) 
was incubated with 100 μl of malachite green 
phosphate detection solution for 15 minutes 
and read at 650 nm. 
Animal xenografts
In the in vivo experiments, we used 8 to 10- 
week-old female nude mice that had been 
strictly inbred at MD Anderson and maintained 
in the MD Anderson Research Animal Support 
Facility in accordance with Institute of Labora- 
tory Animal Research standards. The GSC7-2 
and GSC272 cells (5 × 105) were implanted 
intracranially into the mice, as described previ-
ously [19]. After 3 days, GSK212458 (1.5 mg/
kg, dissolved in 1% DMSO/30% polyethylene 
glycol/1% Tween 80) or LY2874455 (3 mg/kg, 
dissolved in 2% DMSO/30% PEG-300/5% 
Tween 80) was administered intra-gastrically 
once daily for 5 days/week. All animal experi-
ments were approved by the MD Anderson 
Institutional Animal Care and Use Committee. 
Mice that became moribund with neurological 
symptoms were euthanized. Tumor volumes 
were calculated using the formula [(width) × 
(width) × (length)]/2. A survival analysis was 
conducted using the Kaplan-Meier method. 
The mice’s tumor volumes were analyzed using 
an unpaired two-tailed Student t-test, and their 
survival durations were compared using the 
log-rank test. 
Western blot analysis
GSCs were lysed using RIPA lysis buffer (Cell 
Signaling Technology), and samples were sub-
jected to sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis. The separated pro-
teins were electrophoretically transferred to 
polyvinylidene fluoride membranes. Blots were 
incubated with a primary antibody overnight at 
4°C and then incubated with horseradish per-
oxidase-linked secondary anti-rabbit or anti-
mouse antibodies (Bio-Rad). Antibodies against 
phosphorylated AKT (cat. #13038), AKT (cat. 
#9272), phosphorylated mTOR (cat. #2971), 
phosphorylated S6 (cat. #4858), phosphory-
lated 4EBP1 (cat. #9456), phosphorylated ERK 
(cat. #9101), ERK (cat. #9102), 14-3-3 Family 
Antibody Sampler Kit (cat. #9769), K48-lin- 
kage-specific polyubiquitin (cat. #8081), phos-
phorylated FOXO3a (cat. #9465), and FOXO3a 
(cat. #2497) were purchased from Cell Signa- 
ling Technology. CLK2 (cat. #HPA055366), 
14-3-3τ (cat. #SAB2500002), and α-tubulin 
(cat. #T9026) were purchased from Sigma-
Aldrich. Phosphorylated FGFR1 (cat. #PAB0472) 
and HIF-1alpha (cat. #610958) were purchased 
from Abnova and BD Biosciences. Antibodies of 
phosphor PP2A (cat. #1155-1) and PP2A (cat. 
#1512-1) were purchased from Epitomics. The 
results of three independent western blot 




Single cells were plated on precoated poly-L-
lysine coverslips, fixed in methanol for 15 min-
utes at -20°C, rinsed with PBS at least three 
times, blocked in 5% goat serum with 0.2% 
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Triton X-100 for 1 hour, and incubated with spe-
cific antibody overnight. The next day, the slides 
were washed at least three times with PBS and 
0.2% Triton X-100 and incubated with second-
ary antibody for 1 hour. The slides were then 
washed three times and mounted. Patient brain 
tissue samples were fixed in 4% paraformalde-
hyde for 24 hours, embedded in paraffin, sec-
tioned serially (4 μm), and stained with hema-
toxylin and eosin (Sigma-Aldrich). 
For immunohistochemical staining, slides were 
deparaffinized and subjected to graded rehy-
dration. After 3% serum blocking and antigen 
retrieval (citrate buffer, pH 6.0), the slides were 
incubated with primary antibodies overnight at 
4°C. After the slides had been washed in PBS 
with Tween 20, the primary antibody reactions 
were detected using a VECTASTAIN ABC kit 
(Vector Laboratories) with the respective sec-
ondary antibodies. For immunofluorescence 
studies, after blocking, tissue sections were 
incubated with an antibody overnight at 4°C. 
Secondary antibodies (Invitrogen) were incu-
bated for 1 hour at ambient temperature. 
Antibodies against HIF-1alpha (cat. 610958; 
BD Biosciences), CLK2 (cat. #ab188141; Ab- 
cam), and 14-3-3τ (cat. #9638, Cell Signaling 
Technology) were used in the immunohisto-
chemical and immunofluorescence assays. The 
results of three independent experiments per-
formed in triplicate are reported. For TUNEL 
assays in xenografts, slides were examined 
according to the manufacturer’s protocol (in 
situ cell death detection kit, TMR red; Roche).
Detection of multiple signaling pathways using 
reverse-phase protein array
The cells were incubated with specific inhibitors 
for 3 days, and the protein was collected follow-
ing reverse phase protein array (RPPA) sample 
preparation methods. Samples were probed 
with 279 validated primary antibodies for anal-
ysis at the MD Anderson Functional Proteomics 
RPPA. 
Clonogenic formation assay 
To evaluate clonogenic formation, we seeded 
GSCs at 5 cells per well in 96-well plates with 
low-dose inhibitors for 3-4 weeks, in triplicate. 
Wells with neurospheres (> 100 μM) were 
counted as positive, and wells without spheres 
as negative. The percentages of positive neuro-
spheres in each plate were compared among 
different treatment groups.
Statistical analysis
All statistical analyses were conducted using 
the InStat software program for Microsoft 
Windows (GraphPad software). Data were re- 
ported as the mean ± standard deviation. All 
other data were compared using an unpaired 
two-tailed Student t-test. 
Results
CLK2 regulated AKT phosphorylation through 
PP2A activity
CLK2 regulates AKT/FOX3a phosphorylation in 
GSCs [7]. The PP2A holoenzyme comprises a 
structural A subunit, a regulatory B subunit, and 
a catalytic C subunit [9]. Several kinds of B sub-
unit exist: B55 is important to PP2A’s specificity 
for AKT [10], and B56β mediates the insulin-
regulated assembly of the PP2A phosphotase 
holoenzyme complex with CLK2 [8]. 
Treatment with an ATP-competitive CLK2 inhibi-
tor (TG003) resulted in decreased phosphoryla-
tion of AKT T308 and FOXO3a at 40 μM in GSCs 
(Figure 1A). To understand the CLK2-mediated 
inhibition of AKT phosphorylation, we first de- 
termined its upstream regulator PP2A. PP2A 
signaling was determined using a PP2A immu-
noprecipitation phosphatase assay kit. As sh- 
own in Figure 1B, PP2A inhibitor (okadaic acid 
[OA]) significantly inhibited PP2A activity, wh- 
ereas PI3K inhibitor (BKM120) had no effect. 
We confirmed these results in the cell lysate 
used for the phosphatase activity assay using a 
PP2A-specific antibody. PP2A inhibition in- 
creased AKT phosphorylation at T308. Fur- 
thermore, we investigated the role of PP2A in 
CLK2 by using CLK2 knockdown cells; deple-
tion of CLK2 increased PP2A activity (Figure 
1B). Consistent with these results, overexpres-
sion of CLK2 in GSC272 cells resulted in sup-
pression of PP2A activity (Figure 1C) and 
increased cytosolic FOXO3a phosphorylation 
(Figure 1D). Overall, these results indicate that 
CLK2 regulates PP2A activity in brain tumor 
cancer stem cells. 
14-3-3τ regulates the stabilization of CLK2 
14-3-3 proteins are a family of conserved mod-
ulator proteins that regulate multiple signaling 
pathways, including AKT and FOXO3a. 14-3-3 
proteins binds in specific Ser/Thr-phosphory- 
lated motifs on target proteins [12]. Depending 
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Figure 1. CLK2 regulated PP2A activity in GSCs. (A, B) GSC272 cells were treated with the indicated inhibitors-TG003 (CLK inhibitor), OA (PP2A inhibitor), and 
BKM120 (PI3K inhibitor)-for 24 hours and assessed by Western blot analysis and a PP2A activity assay. (C) PP2A activity and FOXO3a phosphorylation were as-
sessed using a PP2A activity assay and (D) an immunofluorescence assay in GSC272 vector, CLK2-overexpressing, and CLK2 knockdown and CLK2-overexpressing 
cells. CLK2, PP2A, and phosphor AKT levels were detected by Western blot analysis. *P < 0.05, **P < 0.01.
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on target binding, 14-3-3 modulates target pro-
tein activity, stability, cellular location, or asso-
ciation [16, 20]. We determined the binding 
affinity of CLK2 with the 14-3-3 isotype; CLK2 
binds with 14-3-3τ, 14-3-3α/β, and PP2A in 
293T cells (Figure 2A). Increasing CLK2 expres-
sion resulted in continued binding affinity with 
14-3-3τ but decreased affinity with PP2A 
(Figure 2B). Overexpression of CLK2 resulted in 
greater binding affinity with 14-3-3τ but not 
with 14-3-3α/β (no change) compared with 
GSC272 vector and less binding affinity with 
phospho-PP2A (Figure 2C). In contrast, lower 
levels of CLK2 in CLK2 shRNA cells led to 
decreased binding affinity with 14-3-3τ and 
increased binding affinity with phospho-pp2A 
(Figure 2D). Furthermore, CLK2 co-localized 
with 14-3-3τ, as revealed by an immunofluores-
cence analysis (Figure 2E). Interestingly, there 
was no direct binding of 14-3-3τ with PP2A in 
the presence of CLK2 in GSCs (Data not shown). 
Since ubiquitination and proteasomal degrada-
tion regulate CLK2 protein stability [11, 21], we 
determined CLK2 stability in the absence of 
14-3-3τ. Depletion of 14-3-3τ resulted in high 
levels of ubiquitination on CLK2 compared with 
that in control cells (Figure 2F), whereas prote-
asome inhibition stimulated the expression of 
CLK2 in control cells but not in 14-3-3τ cells 
(Figure 2G). Overall, our results suggest that 
CLK2 stabilization is regulated by 14-3-3τ in 
glioma stem cells. 
PI3K/mTOR and FGFR inhibitors demonstrate 
synergistic effects on CLK2 knockdown glioma 
stem cell viability 
In the present study, we identified therapies 
that are synergistic against glioblastoma when 
combined with CLK2 knockdown. Inhibitors of 
mTOR, FGFR, EGFR, and ERK were tested in 
parental and CLK2 knockdown glioma stem-
like cell lines (Figure 3A). In GSC7-2, GSC272, 
and GSC20 cells, treatment with mTOR inhibi-
tor (GSK2126458) in CLK2 knockdown cell 
lines led to significant reductions in cell viability 
compared to drug treatment alone at a lower 
dose. Furthermore, the combination of FGFR 
inhibitor (LY2874455) and CLK2 knockdown 
decreased viability synergistically in GSC7-2 
and GSC272 cells, at a high concentration. 
EGFR and MEK inhibitors had no combined 
effect in the viability assay. Depletion of CLK2 
induced G1 phase cell cycle arrest, and the 
combination of CLK2 knockdown and mTOR 
inhibitor or FGFR inhibitors increased sub-G1 
phase, suggesting apoptosis induction (Figure 
3B). 
To determine whether PI3K/mTOR and FGFR 
inhibitors induce apoptosis in CLK2 knockdown 
cell lines, we performed an annexin V/DAPI 
assay in control and CLK2 knockdown GSCs, 
with and without inhibitor (Figure 3C). PI3K/
mTOR and FGFR inhibitors induced apoptosis in 
a dose-dependent manner. Treatment with 
FGFR inhibitors in CLK2 knockdown cell lines 
led to synergistic apoptosis induction com-
pared to drug treatment alone. Treatment with 
inhibitors in CLK2 knockdown lines led to 
decreased colony formation compared to drug 
treatment alone in GSC7-2 cells (Figure 3D). 
Our findings suggest that the combination of 
CLK2 knockdown and PI3K/mTOR or FGFR 
inhibitors synergistically induces apoptosis in 
GSCs. 
Effect of PI3K/mTOR (GSK2126458) and 
FGFR (LY2874455) inhibitors on GSC viability 
We first examined the inhibitory effect of 
GSK2126458 and LY2874455 in glioma stem 
cells. GSK2126458, a dual PI3K/mTOR, had 
the lowest IC50 values for all the GSCs tested (< 
0.5 μM) (Figure 4A). The response of 
LY2874455, an FGFR inhibitor, to FGFR inhibi-
tion was found to be cell line specific (Figure 
4A). GSC262, GSC280, GSC11, GSC23, GSC- 
274, GSC7-2, GSC231, GSC295, and GSC300 
cells were the most responsive, with IC50s of < 3 
μM; GSC272, GSC8-11, GSC6-27, GSC20, 
GSC17, and GSC28 cells were the most resis-
tant, with IC50s of > 3 μM. 
To confirm that the drug targets are expressed 
and modulated by drug treatment, we evaluat-
ed PTEN and FGFR by real-time PCR (Figure 
4B). PTEN expression levels were correlated 
with the IC50s of GSK2126458. The more sensi-
tive cell lines had higher total expression levels 
of FGFR1 than did the resistant cell lines. 
We determined relative protein expression lev-
els after treatment with the IC50 dose of inhibi-
tor using RPPA (Figure 4C). Phosphorylation 
of mTOR, AKT, S6 kinase (ribosomal protein 
S6), and 4EBP1 (eukaryotic initiation factor 4E 
binding protein 1) was decreased in a dose- 
dependent manner following treatment with 
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Figure 2. CLK2 binding with 14-3-3τ increased stability via a degradation mechanism. A-F. CLK2-overexpressing 293T cells, CLK2-overexpressing or CLK2 knock-
down GSC272 cells, and 14-3-3τ knockdown GSC272 cells were collected and assessed using an immunoprecipitation assay and immunofluorescence staining. 
Representative images showed that showed that 14-3-3τ (red) co-localized with CLK2 (green) in GSC272 cells. The nucleus stained with DAPI, blue. G. GSC272 cells 
were pretreated with the indicated amounts of MG132 for 2 hours in serum-free media, and bFGF/EGF was added at the same concentrations as complementary 
media for 4 hours. The bar graph shows densitometric quantification of western blot bands (n=2). *P < 0.05 compared to vector cells.
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Figure 3. PI3K/mTOR or FGFR inhibitors decreased cell viability and the cell cycle in CLK2-depleted cells. A. GSCs were treated with inhibitors of EGFR (Tarceva), ERK 
(PD98059), PI3K/mTOR (GSK2124658), and FGFR (LY2874455) in vector and CLK2-depleted cells for 5 days (viability). Cell viability was detected by CellTiter-Glo. 
B, C. GSC272 cells were incubated with PI3K/mTOR (GSK2124658) and FGFR (LY2874455) for 1 day (cell cycle) or 3 days (apoptosis), collected, and washed two 
times. B. For cell cycle analysis, cells were incubated with 70% EtOH at -20°C for 1 day and washed three times with PBS and stained with propidium iodide. C. For 
apoptosis assay, the cells were stained with annexin V-APC, DAPI. Apoptosis and the cell cycle were detected using a FACS analysis. D. A colony formation assay was 
done in GSC 7-2 cells treated with lower dose of PI3K/mTOR and FGFR inhibitors. The results are presented as the percentage of the control. *P < 0.05, **P < 0.01.
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GSK2126458 (Figure 4D). Phosphorylation of 
FGFR1 and STAT3 was decreased in a dose-
dependent fashion upon treatment with FGFR 
inhibitor, but phosphorylation of ERK was in- 
creased. We tested GSK2126458 and LY- 
2874455 in vivo (Figure 4E). GSK2126458 pro- 
longed the survival of GSC272 but not GSC7-2 
cells; LY2874455 did not prolong the survival of 
either of these cell lines.
Depletion of CLK2 enhanced the effect of 
FGFR inhibitors in GSCs 
GSC272 and GSC7-2 cells with CLK2 shRNA#1 
and CLK2shRNA#2 were implanted into the 
brains of nude mice. Each shRNA#2 GSCs led 
to significantly prolonged mouse survival com-
pared to control cells (Figure 5A). As shown in 
Figure 4E, FGFR inhibitors had no effect on sur-
vival in GSC272 and GSC7-2 mouse models 
despite their in vitro activity as single agents. 
We used PI3K/mTOR or FGFR inhibitors in 
CLK2-depleted cells and control cell-implanted 
mice. Knockdown of CLK2 led to prolonged sur-
vival but had no synergistic effect with PI3K/
mTOR or FGFR inhibitors (Figure 5B). Com- 
bination therapy resulted in similar survival out-
comes in CKL2 wildtype cells to those found in 
CLK2 knockdown cell lines. Although there was 
no significant change in CLK2 inhibition with 
combination therapy, tumor growth was signifi-
cantly decreased after CLK2 knockdown in 
GSC272 mice treated with PI3K/mTOR or FGFR 
inhibitors compared with that in control mice 
(Figure 5C). In GSC7-2 mice, tumor growth was 
significantly decreased after CLK2 knockdown 
and PI3K/mTOR inhibitor treatment compared 
with vector treated controls. FGFR inhibitor 
treatment resulted in a significant decrease in 
tumor growth in CLK2 knockdown GSC272 
cells compared with that in vehicle-treated 
cells. 
Combination of CLK2 depletion with PI3K/
mTOR and FGFR inhibitors blocked HIF-1alpha 
expression and increased the number of apop-
totic cells in vivo
Individual treatment with mTOR and FGFR 
inhibitors had no effect on apoptosis in in vivo, 
but treatment with these agents in CLK2 knock-
down tumors resulted in significant apoptotic 
cell death (Figure 6A). CLK2 knockdown pro-
longed animal survival, and an examination of 
tumors demonstrated a high level of HIF-1alpha 
expression. mTOR and FGFR inhibitors led to 
decreased HIF-1alpha expression, and the 
combination of CLK2 knockdown and either 
inhibitor decreased it further (Figure 6B). We 
confirmed HIF-1alpha expression by analyzing 
RPPA data in vitro; a heatmap demonstrated 
that CLK2 knockdown combined with PI3K/
mTOR and FGFR inhibitors led to decreased 
HIF-1alpha expression (Figure 6C). These 
results showed that combination therapy had a 
greater effect on apoptosis and hypoxia-related 
resistance in the GSC mouse model. 
Discussion
In our previous study, we determined CLK2’s 
function in glioblastoma and correlated its pos-
itive expression with poor outcome [7]. CLK2 
plays a role in controlling the cell cycle and sur-
vival through FOXO3a/p27. In this study, we 
investigated the molecular mechanism of CLK2 
in GSC proliferation and identified 14-3-3τ as a 
significant regulator. Our results suggest that 
14-3-3 proteins contribute to FOXO3 accumula-
tion following phosphorylation by AKT. 
PP2A is effective at FOXO3 dephosphorylation 
[22]. The results of our current study suggest 
that the depletion of CLK2 elevated PP2A activ-
ity, which in turn, abolished AKT phosphoryla-
tion in GSCs. Furthermore, we showed that 
CLK2 bound with 14-3-3α/β, 14-3-3τ, and PP- 
Figure 4. Effect of PI3K/mTOR or FGFR inhibitors on GSCs. A. Several GSCs were treated with serial doses of inhibi-
tors for 5 days; a volume of CellTiter-Glo reagent was added, and the luminescence was recorded. B. The cells were 
collected, and PTEN and FGFR mRNA levels were determined by real-time PCR. C. The cells were treated with the 
IC50 value of inhibitors for 3 days, and the protein expression levels were analyzed by RPPA. Heatmaps from different 
proteins were used to compare treatment with no treatment and show the predicted targets of inhibitors. D. GSCs 
were treated with 1/3 IC50 and 1/2 IC50 concentrations of GSK2126458 or LY2874455 for 24 hours. The indicated 
protein expression was assessed by Western blot analysis. E. GSC272 and GSC7-2 cells were implanted in the 
brains of immunocompromised mice (5 × 105 cells/mouse) and treated with inhibitors 5 times/week. Kaplan-Meier 
curves of the estimated survival durations of the study mice. In the GSC272 group, we compared control and mTOR 
inhibitors (*P < 0.05). 
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Figure 5. Effect of PI3K/mTOR or FGFR inhibitors on depletion of CLK2 GSCs and survival of mice. A, B. CLK2 knock-
down or vector GSCs were implanted in the brains of immunocompromised mice; the mice were then given inhibi-
tors 5 times/week. Kaplan-Meier curves of the estimated survival durations of study mice. In the GSC272 group, 
the following were compared: vector and CLK2 shRNA-infected cell implantation (**P < 0.01) and vector and PI3K/
mTOR inhibitor (*P < 0.05). In the GSC7-2 mice, the following were compared: vector versus CLK2 shRNA-infected 
cell implantation (***P < 0.001), FGFR inhibitor versus FGFR inhibitor and CLK2 knockdown (***P < 0.001), and 
PI3K/mTOR inhibitor versus PI3K/mTOR inhibitor and CLK2 knockdown (***P < 0.001). C. Mice with knockdown 
of CLK2 (shRNA1 and shRNA2) had smaller tumors than did control mice (*P < 0.05 in GSC272 mice; *P < 0.05 
in GSC7-2 mice). Treatment with PI3K/mTOR inhibitor resulted in decreased tumor size (*P < 0.05 vs vector in 
GSC272 mice, **P < 0.001 vs vector in GSC7-2 mice). Treatment with FGFR inhibitor resulted in decreased tumor 
size (**P < 0.01 vs vector in GSC272 mice; no significant difference was found in GSC7-2 mice). The combination 
of FGFR inhibitors and CLK2 knockdown resulted in decreased tumor size compared with CLK2 knockdown alone 
(**P < 0.01). 
2A; 14-3-3τ had a positive binding affinity with 
CLK2 expression, and PP2A had a negative 
binding affinity in glioma cancer cells. In hepa-
tocytes, CLK2 is upregulated by insulin induc-
tion to homeostatically regulate AKT through 
B56β/PP2A-mediated dephosphorylation [8]. 
In addition, PP2A contributes to the regulation 
of 14-3-3 binding to BAD [23] and the dephos-
phorylation of Raf-1 and KRS1 [24]. Most of the 
14-3-3 binding proteins are phosphorylated 
either at R(S/Ar)XpSXP (mode 1) or RX(Ar/S)
XpSXP (mode 2) consensus motifs [20, 25]. 
Besides these consensus motifs, 14-3-3 inter-
actions are further regulated by the phosphory-
lation of other residues within consensus bind-
ing motifs and serine/threonine residues [26]. 
In this study, we established that CLK2 binds 
with 14-3-3 and interestingly, that CLK2 has a 
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Figure 6. Treatment with inhibitor in CLK2 knockdown mice increased the number of apoptotic cells and arrested HIF-1alpha expression in vivo. A. Apoptotic cells 
are marked as light red dots after TUNEL staining, as observed under a fluorescent microscope. Nuclei were stained with DAPI (blue). Apoptotic cells were counted, 
and the number of TUNEL-positive cells was graphed. The graphs show the number of apoptotic cells ± SD (***P < 0.001). B. Immunofluorescent staining are 
shown for HIF-1alpha in GSC7-2 mouse glioma xenografts, with or without treatment with CLK2 knockdown or vector cells. HIF-1alpha (red) and nucleus (DAPI, blue) 
were expressed at CLK2 knockdown but decreased with inhibitor and combination treatment. C. The cells were treated with the IC50 value of inhibitors for 3 days, 
and the protein expression levels were analyzed by RPPA. A heatmap shows HIF-1alpha expression levels in GSC272 and GSC7-2 cells.
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serine/threonine phosphorylation site. Addi- 
tional studies are required to identify the phos-
phorylation sites that are important for CLK2’s 
binding with 14-3-3. 
The results of previous studies suggest that 
CLK2 protein stability is regulated by ubiquiti-
nation and proteasomal degradation [11, 21]. 
Indeed, co-expression of Flag-CLK2 with HA- 
tagged ubiquitin resulted in low levels of ubiqui-
tination on WT CLK2. In our current study, we 
found high expression of CLK2; we also ob- 
served binding of CLK2 with 14-3-3 in GSCs, 
which prevents CLK2 ubiquitination and stabi-
lizes CLK2 in GSCs. Interestingly, knockdown of 
CLK2 expression shifted binding affinity with 
PP2A and decreased AKT phosphorylation. 
14-3-3τ (YWHAQ) is required for the G1/S tran-
sition through its role in ubiquitin-independent 
proteasomal degradation of p21 [27]. These 
results indicate that 14-3-3 protein is a master 
switch that leads to CLK2 stabilization and 
decreased PP2A activity and influences AKT 
phosphorylation in glioblastoma stem cells. 
mTOR is downstream of the PI3K/AKT pathway, 
which consists of mTOR complex 1 (mTORC1) 
and mTOR complex 2 (mTORC2) [28]. mTORC1 
activates protein translation through the phos-
phorylation of S6 and 4EBP1. Early-generation 
inhibitors of mTOR had limited antitumor activi-
ty because allosteric inhibitors such as rapamy-
cin block mTORC1 but not mTORC2 [29]. In our 
study, we first confirmed the strong inhibitory 
effect of GSK2126458 on glioblastoma cell 
viability. The sensitivity of this inhibition was 
correlated with PTEN levels: cells with higher 
mRNA levels of PTEN (GSC7-2, GSC17, GSC295, 
and GSC28) were more resistant to GSK- 
2126458. DS7423 (PI3/mTOR inhibitor) was 
associated with PTEN alteration in glioblasto-
ma [30]. In animal studies, 3 mg/kg of GSK- 
2126458 was found to result in weight loss; 
therefore, we decreased the dose to 1.5 mg/kg 
[5, 31]. More interestingly, the sensitivity of 
phospho-4EBP1 was correlated with the viabil-
ity of GSCs. GSC20 cells were the most resis-
tant; treatment with GSK2126458 had no 
effect on phosphor-4EBP1, unlike in GSC272 
and GSC7-2 cells. 
The mTORC1 target p-4EBP1T37/46 is a robust 
biomarker [32]. FGFR-TACC gene fusions in glio-
blastoma result in aggressive clinical behavior 
[33]. FGFR1 is expressed at high levels in brain 
tumors compared with in adjacent normal brain 
tissue, and its role has been established in 
tumorigenesis [34]. FGFR1 amplification has 
been found in 6% of small cell lung carcinomas 
[35] and is correlated with sensitivity to FGFR 
inhibitors [36, 37]. In our study, FGFR1 mRNA 
was expressed at higher levels than was the 
mRNA of other FGFR subtypes, and FGFR1 
expression was influenced by the FGFR inhibi-
tor LY2874455. FGFR inhibition resulted in a 
decrease in AKT phosphorylation, HIF-1alpha 
expression, and STAT3 phosphorylation. These 
findings suggest that FGFR inhibitor affects the 
STAT3/HIF-1alpha pathway in vitro and decreas-
es HIF-1alpha levels in vivo in GSCs. 
In our study, GSK2126458 and LY2874455 
inhibitors had activity in GSCs in vitro but less 
significant effects in our preclinical orthotopic 
in vivo models. Since both inhibitors may have 
limited blood brain barrier penetration, this 
might account for the limited activity observed 
in our in vivo xenograft models. As with so many 
failed translations of studies from preclinical 
models to patients, future drug development 
should emphasize the use of agents with excel-
lent blood-brain barrier permeability to opti-
mize the treatment of glioblastoma. 
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